Press Releases – NASDAQ (US) Website

Press Releases

Jul 20, 2018
BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited    read more...
Jul 03, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)    read more...
Jun 15, 2018
BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association    read more...
Jun 06, 2018
BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference    read more...
Jun 05, 2018
BeiGene to Present at the William Blair 2018 Growth Stock Conference    read more...
Jun 01, 2018
BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23rd Congress of the European Hematology Association    read more...
May 17, 2018
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer    read more...
May 15, 2018
BeiGene to Present at the 2018 UBS Global Healthcare Conference    read more...
May 09, 2018
BeiGene Reports First Quarter 2018 Financial Results    read more...
May 04, 2018
BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference    read more...
May 01, 2018
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.    read more...
Apr 16, 2018
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting    read more...
Apr 16, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas    read more...
Apr 10, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma    read more...
Apr 03, 2018
BeiGene Appoints J. Samuel Su to its Board of Directors    read more...
Mar 05, 2018
BeiGene to Present at Upcoming Investor Conferences    read more...
Feb 28, 2018
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results    read more...
Feb 27, 2018
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China    read more...
Feb 09, 2018
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium    read more...
Feb 07, 2018
BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference    read more...